{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:01:12Z","timestamp":1783814472103,"version":"3.55.0"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kyowa Kirin International"},{"name":"OPEN Health"},{"name":"OPEN Health"},{"name":"Afsaneh Khetrapal of ApotheCom"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The importance of patient centricity and keeping the patient at the heart of research design is now well recognised within the healthcare community. The involvement of patient, caregiver and clinician representatives in the study design process may help researchers to achieve this goal and to ensure robust and meaningful data generation. Real-world data collection allows for a more flexible and patient-centred research approach for gaining important insights into the experience of disease and treatments, which is acutely relevant for rare diseases where knowledge about the disease is more likely to be limited. Here, we describe a practical example of a patient-centric, multi-stakeholder approach that led to the co-design of a prospective observational study investigating the lived experience of adolescents with the rare disease, X-linked hypophosphataemia. Specifically, we describe how the knowledge and expertise of a diverse research team, which included expert physicians, research and technology specialists, patients and caregivers, were applied in order to identify the relevant research questions and to ensure the robustness of the study design and its appropriateness to the population of interest within the context of the current clinical landscape. We also demonstrate how a structured patient engagement exercise was key to informing the selection of appropriate outcome measures, data sources, timing of data collection, and to assessing the feasibility and acceptability of the proposed data collection approach.<\/jats:p>","DOI":"10.1371\/journal.pone.0295080","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T18:33:28Z","timestamp":1705689208000},"page":"e0295080","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["A patient-centred and multi-stakeholder co-designed observational prospective study protocol: Example of the adolescent experience of treatment for X-linked hypophosphataemia (XLH)"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3601-8942","authenticated-orcid":true,"given":"Vrinda","family":"Saraff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke M.","family":"Boot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3455-002X","authenticated-orcid":true,"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0029-7556","authenticated-orcid":true,"given":"Oliver","family":"Semler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pol","family":"Harvengt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1985-4826","authenticated-orcid":true,"given":"Karen M. A.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Glen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin Haf","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Greentree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J.","family":"Rylands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"issue":"3","key":"pone.0295080.ref001","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/1878-0261.12431","article-title":"Late translational research: Putting forward a new model for developing new anti-cancer treatments that addresses the needs of patients and society","volume":"13","author":"D Lacombe","year":"2019","journal-title":"Mol Oncol"},{"issue":"4","key":"pone.0295080.ref002","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jval.2014.02.012","article-title":"Patient-centeredness in the design of clinical trials","volume":"17","author":"CD Mullins","year":"2014","journal-title":"Value Health"},{"issue":"6","key":"pone.0295080.ref003","doi-asserted-by":"crossref","first-page":"e1002049","DOI":"10.1371\/journal.pmed.1002049","article-title":"Why most clinical research is not useful","volume":"13","author":"JP Ioannidis","year":"2016","journal-title":"PLoS Med"},{"issue":"2","key":"pone.0295080.ref004","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01870-2018","article-title":"Moving forward from drug-centred to patient-centred research: A white paper initiated by EORTC and developed together with the BioMed Alliance members","volume":"53","author":"D Lacombe","year":"2019","journal-title":"Eur Respir J"},{"key":"pone.0295080.ref005","doi-asserted-by":"crossref","first-page":"l4340","DOI":"10.1136\/bmj.l4340","article-title":"New drugs: where did we go wrong and what can we do better?","volume":"366","author":"B Wieseler","year":"2019","journal-title":"BMJ"},{"key":"pone.0295080.ref006","unstructured":"EPRS (European Parliamentary Research Service). Treatment optimisation in drug development 2020. https:\/\/www.europarl.europa.eu\/RegData\/etudes\/STUD\/2020\/641511\/EPRS_STU(2020)641511_EN.pdf."},{"issue":"6","key":"pone.0295080.ref007","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jval.2020.01.019","article-title":"Defining patient engagement in research: Results of a systematic review and analysis: Report of the ISPOR Patient-Centered Special Interest Group","volume":"23","author":"RL Harrington","year":"2020","journal-title":"Value Health"},{"issue":"9","key":"pone.0295080.ref008","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/pds.4297","article-title":"Good practices for real-world data studies of treatment and\/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making","volume":"26","author":"ML Berger","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0295080.ref009","unstructured":"Patient-Centred Outcomes Research Institute (PCORI). [cited 2021 10 Nov]. https:\/\/www.pcori.org\/."},{"key":"pone.0295080.ref010","unstructured":"U.S. Food and Drug Administration. Patient-focused drug development: Collecting comprehensive and representative input 2018 [cited 2021 10 Nov]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input."},{"key":"pone.0295080.ref011","unstructured":"U.S. Food and Drug Administration. Patient-focused drug development: Methods to identify what is important to patients 2019 [cited 2021 10 Nov]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients."},{"key":"pone.0295080.ref012","unstructured":"Innovative Medicines Initiative. Paradigm. Patients active in research and dialogues for an improved generation of medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes [cited 2021 16 Aug]. https:\/\/www.imi.europa.eu\/projects-results\/project-factsheets\/paradigm."},{"key":"pone.0295080.ref013","unstructured":"National Institute for Health Research. What is public involvement in research? [cited 2021 12 Oct]. https:\/\/www.invo.org.uk\/find-out-more\/what-is-public-involvement-in-research-2\/."},{"issue":"2","key":"pone.0295080.ref014","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/2168479017716715","article-title":"Assessing the financial value of patient engagement: A quantitative approach from CTTI\u2019s Patient Groups and Clinical Trials Project","volume":"52","author":"B Levitan","year":"2018","journal-title":"Ther Innov Regul Sci"},{"issue":"23","key":"pone.0295080.ref015","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014what is it and what can it tell us?","volume":"375","author":"RE Sherman","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0295080.ref016","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jval.2020.04.002","article-title":"Improving transparency to build trust in real-world secondary data studies for hypothesis testing-why, what, and how: Recommendations and a road map from the Real-World Evidence Transparency Initiative","volume":"23","author":"LS Orsini","year":"2020","journal-title":"Value Health"},{"issue":"5","key":"pone.0295080.ref017","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s12325-019-00920-x","article-title":"The case for the use of patient and caregiver perception of change assessments in rare disease clinical trials: A methodologic overview","volume":"36","author":"MG Contesse","year":"2019","journal-title":"Adv Ther"},{"issue":"3","key":"pone.0295080.ref018","doi-asserted-by":"crossref","first-page":"A12","DOI":"10.7326\/ACPJC-1995-123-3-A12","article-title":"The well-built clinical question: a key to evidence-based decisions","volume":"123","author":"WS Richardson","year":"1995","journal-title":"ACP J Club"},{"issue":"3","key":"pone.0295080.ref019","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1741-6787.2005.00032.x","article-title":"Teaching EBP: Asking searchable, answerable clinical questions","volume":"2","author":"E Fineout-Overholt","year":"2005","journal-title":"Worldviews Evid Based Nurs"},{"issue":"3","key":"pone.0295080.ref020","doi-asserted-by":"crossref","first-page":"e1249","DOI":"10.1210\/clinem\/dgab739","article-title":"Musculoskeletal features in adults with X-Linked hypophosphatemia: An analysis of clinical trial and survey data","volume":"107","author":"MK Javaid","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"pone.0295080.ref021","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician\u2019s guide to X-Linked hypophosphatemia","volume":"26","author":"TO Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"4","key":"pone.0295080.ref022","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/sca.21141","article-title":"X-Linked hypophosphatemic rickets: Enamel abnormalities and oral clinical findings","volume":"36","author":"I Cremonesi","year":"2014","journal-title":"Scanning"},{"issue":"1","key":"pone.0295080.ref023","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"A Linglart","year":"2014","journal-title":"Endocr Connect"},{"issue":"3","key":"pone.0295080.ref024","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-Linked hypophosphatemia and skeletal symptoms","volume":"174","author":"H Che","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"pone.0295080.ref025","first-page":"204","article-title":"A qualitative analysis of the burden-of-illness associated with X-Linked hypophosphataemia (XLH) in children and adolescents","volume":"7","author":"N Ferizovic","year":"2019","journal-title":"Bone Abstracts"},{"issue":"7","key":"pone.0295080.ref026","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong Impact of X-Linked hypophosphatemia: Results from a burden of disease survey","volume":"3","author":"A Skrinar","year":"2019","journal-title":"J Endocr Soc"},{"issue":"8","key":"pone.0295080.ref027","doi-asserted-by":"crossref","first-page":"bvab070","DOI":"10.1210\/jendso\/bvab070","article-title":"Patient-reported complications, symptoms, and experiences of living with X-Linked hypophosphatemia across the life-course","volume":"5","author":"M Cheung","year":"2021","journal-title":"J Endocr Soc"},{"key":"pone.0295080.ref028","doi-asserted-by":"crossref","first-page":"1034580","DOI":"10.3389\/fendo.2022.1034580","article-title":"Burosumab for X-Linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries","volume":"13","author":"MZ Mughal","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"pone.0295080.ref029","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"D Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"pone.0295080.ref030","unstructured":"European Medicines Agency. Summary of product characteristics, Crysvita 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/crysvita-epar-product-information_en.pdf."},{"issue":"1","key":"pone.0295080.ref031","first-page":"99","article-title":"Assessment of quality of life of parents of children with osteogenesis imperfecta","volume":"21","author":"A Szczepaniak-Kubat","year":"2012","journal-title":"Adv Clin Exp Med"},{"issue":"3","key":"pone.0295080.ref032","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.dhjo.2014.03.002","article-title":"Shaping and managing the course of a child\u2019s disease: parental experiences with osteogenesis imperfecta","volume":"7","author":"MJ Dogba","year":"2014","journal-title":"Disabil Health J"},{"issue":"7","key":"pone.0295080.ref033","first-page":"764","article-title":"Difficulties experienced by caregivers of patients diagnosed with osteogenesisimperfecta (OI): Example of a hospital","volume":"65","author":"LB Arabaci","year":"2015","journal-title":"J Pak Med Assoc"},{"key":"pone.0295080.ref034","doi-asserted-by":"crossref","first-page":"S865","DOI":"10.1016\/j.jval.2019.09.2461","article-title":"PRO132 disease burden of X-Linked hypophosphatemia","volume":"22","author":"M Yanes","year":"2019","journal-title":"Value in Health"},{"key":"pone.0295080.ref035","volume-title":"Foundations of mixed methods research: Integrating quantitative and qualitative approaches in the social and behavioral sciences","author":"C Teddlie","year":"2009"},{"key":"pone.0295080.ref036","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3102\/01623737011003255","article-title":"Towards a conceptual framework for mixed-method evaluation designs","volume":"11","author":"JC Greene","year":"1989","journal-title":"Educational Evaluation and Policy Analysis"},{"key":"pone.0295080.ref037","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3102\/0013189X033007014","article-title":"Mixed methods research: A research paradigm whose time has come","volume":"33","author":"R Burke Johnson","year":"2004","journal-title":"Educational Researcher"},{"issue":"1","key":"pone.0295080.ref038","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40670-019-00898-9","article-title":"A medical science educator\u2019s guide to selecting a research paradigm: Building a basis for better research","volume":"30","author":"MEL Brown","year":"2020","journal-title":"Med Sci Educ"},{"key":"pone.0295080.ref039","volume-title":"Designing and conducting mixed methods research","author":"JW Creswell","year":"2017","edition":"9"},{"key":"pone.0295080.ref040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF02766777","article-title":"ERIC\/ECTJ annual review paper: Criteria for assessing the trustworthiness of naturalistic inquiries","volume":"25","author":"EG Guba","year":"1981","journal-title":"Educational Communication and Technology"},{"key":"pone.0295080.ref041","volume-title":"Qualitative research methods for the social sciences","author":"BL Berg","year":"2001","edition":"4"},{"key":"pone.0295080.ref042","volume-title":"Qualitative research and evaluation methods","author":"MQ Patton","year":"2002","edition":"3"},{"key":"pone.0295080.ref043","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1525822X05279903","article-title":"How many interviews are enough?: An experiment with data saturation and variability","volume":"18","author":"G Guest","year":"2006","journal-title":"Field Methods"},{"issue":"8","key":"pone.0295080.ref044","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-Linked hypophosphatemia: Week 24 primary analysis","volume":"33","author":"KL Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"10189","key":"pone.0295080.ref045","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-Linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"EA Imel","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"pone.0295080.ref046","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001714","article-title":"Burosumab treatment in adults with X-Linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension","volume":"7","author":"K Briot","year":"2021","journal-title":"RMD Open"},{"issue":"5","key":"pone.0295080.ref047","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00223-020-00797-x","article-title":"Patient-reported outcomes from a randomized, active-controlled, open-label, phase 3 trial of burosumab versus conventional therapy in children with X-Linked hypophosphatemia","volume":"108","author":"R Padidela","year":"2021","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"pone.0295080.ref048","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","article-title":"Continued beneficial effects of burosumab in adults with X-Linked hypophosphatemia: Results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period","volume":"105","author":"AA Portale","year":"2019","journal-title":"Calcif Tissue Int"},{"key":"pone.0295080.ref049","doi-asserted-by":"crossref","first-page":"S710","DOI":"10.1016\/j.jval.2020.08.1851","article-title":"PRO115 a patient-centric approach to designing a mixed-methods observational study involving adolescents with X-Linked hypophosphatemia","volume":"23","author":"AJ Rylands","year":"2020","journal-title":"Value in Health"},{"issue":"1","key":"pone.0295080.ref050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jval.2018.11.001","article-title":"EQ-5D-Y as a health-related quality of life instrument for children and adolescents: The instrument\u2019s characteristics, development, current use, and challenges of developing its value set","volume":"22","author":"S Kreimeier","year":"2019","journal-title":"Value Health"},{"key":"pone.0295080.ref051","unstructured":"EuroQol. EQ-5D-Y (Youth) 2021 [cited 2021 13 Jan]. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-y-about\/."},{"key":"pone.0295080.ref052","first-page":"UK2014","volume-title":"Qualitative research practice","author":"J Ritchie"},{"key":"pone.0295080.ref053","unstructured":"National Institute for Health and Care Research. PPI (Patient and Public Involvement) resources for applicants to NIHR research programmes [cited 10 Nov 2021]. https:\/\/www.nihr.ac.uk\/documents\/ppi-patient-and-public-involvement-resources-forapplicants-to-nihr-research-programmes\/23437."},{"issue":"1","key":"pone.0295080.ref054","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13023-017-0718-x","article-title":"Measuring what matters to rare disease patients\u2014reflections on the work by the IRDiRC taskforce on patient-centered outcome measures","volume":"12","author":"T Morel","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"pone.0295080.ref055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13023-018-0835-1","article-title":"How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial","volume":"13","author":"M Bharmal","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"pone.0295080.ref056","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.sleep.2011.03.016","article-title":"No pain, no gain: an exploratory within-subjects mixed-methods evaluation of the patient experience of sleep restriction therapy (SRT) for insomnia","volume":"12","author":"SD Kyle","year":"2011","journal-title":"Sleep Med"},{"key":"pone.0295080.ref057","doi-asserted-by":"crossref","first-page":"688309","DOI":"10.3389\/fendo.2021.688309","article-title":"X-Linked Hypophosphatemic Rickets: Multisystemic Disorder in Children Requiring Multidisciplinary Management","volume":"12","author":"GI Baroncelli","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"pone.0295080.ref058","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3390\/endocrines3030032","article-title":"X-Linked Hypophosphatemia Transition and Team Management","volume":"3","author":"T. Kubota","year":"2022","journal-title":"Endocrines"},{"issue":"1","key":"pone.0295080.ref059","first-page":"029","article-title":"Defining a growing and maturing skeleton and its relevance in diseases that affect skeletal growth, such as X-Linked hypophosphataemia (XLH)","volume":"4","author":"SS Becks-Nielsen","year":"2021","journal-title":"Int J Rare Dis Disord"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295080","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T18:33:55Z","timestamp":1705689235000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295080"}},"subtitle":[],"editor":[{"given":"Domenico","family":"Rendina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0295080","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]}}}